Zacks: Analysts Anticipate Alnylam Pharmaceuticals, Inc. (ALNY) Will Post Quarterly Sales of $32.43 Million
Wall Street brokerages expect Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to post sales of $32.43 million for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Alnylam Pharmaceuticals’ earnings, with estimates ranging from $11.00 million to $67.93 million. Alnylam Pharmaceuticals reported sales of $18.96 million in the same quarter last year, which indicates a positive year over year growth rate of 71%. The company is expected to issue its next earnings report on Friday, May 4th.
According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full year sales of $32.43 million for the current year, with estimates ranging from $13.74 million to $167.40 million. For the next fiscal year, analysts forecast that the firm will report sales of $287.96 million per share, with estimates ranging from $189.20 million to $435.03 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative return on equity of 41.08% and a negative net margin of 545.95%. The firm had revenue of $37.90 million during the quarter, compared to analyst estimates of $19.31 million. During the same quarter in the previous year, the firm posted ($1.32) earnings per share. The company’s quarterly revenue was up 116.6% on a year-over-year basis.
Alnylam Pharmaceuticals (ALNY) traded up $1.56 during mid-day trading on Wednesday, reaching $121.42. The company had a trading volume of 391,354 shares, compared to its average volume of 879,798. The company has a current ratio of 12.23, a quick ratio of 12.23 and a debt-to-equity ratio of 0.02. Alnylam Pharmaceuticals has a 12 month low of $45.00 and a 12 month high of $147.63. The firm has a market cap of $12,090.00, a PE ratio of -22.44 and a beta of 2.68.
In other news, SVP Laurie Keating sold 30,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the sale, the senior vice president now owns 41,500 shares of the company’s stock, valued at approximately $5,639,435. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Michael Mason sold 36,745 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the sale, the vice president now directly owns 6,352 shares in the company, valued at approximately $835,859.68. The disclosure for this sale can be found here. Insiders sold a total of 72,994 shares of company stock worth $9,669,353 over the last three months. Corporate insiders own 4.30% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in ALNY. Parametric Portfolio Associates LLC raised its position in shares of Alnylam Pharmaceuticals by 8.2% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 64,943 shares of the biopharmaceutical company’s stock valued at $5,180,000 after buying an additional 4,913 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Alnylam Pharmaceuticals by 59.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 179,429 shares of the biopharmaceutical company’s stock valued at $14,311,000 after buying an additional 66,651 shares during the period. QS Investors LLC raised its position in shares of Alnylam Pharmaceuticals by 59.7% during the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 900 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Alnylam Pharmaceuticals by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 167 shares during the period. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $540,000. 88.61% of the stock is currently owned by hedge funds and other institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.